Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack A Cook

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
The AAPS Journal|December 3, 2020
Correction to: Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug ProductsArzu Selen, Anette Müllertz, Filippos Kesisoglou, et al.
Rapid Communications in Mass Spectrometry : RCM|April 30, 2003
Investigation of EDTA anticoagulant in plasma to improve the throughput of liquid chromatography/tandem mass spectrometric assaysNalini P Sadagopan, Wenlin Li, Jack A Cook, et al.
Clinical Pharmacology and Therapeutics|April 5, 2022
Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance StudiesArnab Mukherjee, Shinichi Tsuchiwata, Timothy Nicholas, et al.
Molecular Pharmaceutics|December 23, 2009
Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studiesJack A Cook, Bo Feng, Katherine S Fenner, et al.
The AAPS Journal|June 3, 2010
Meeting report: applied biopharmaceutics and quality by design for dissolution/release specification setting: product quality for patient benefitArzu Selen, Maria T Cruañes, Anette Müllertz, et al.
Journal of Pharmaceutical Sciences|September 24, 2016
Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring GridPaul A Dickinson, Filippos Kesisoglou, Talia Flanagan, et al.
Clinical Pharmacology and Therapeutics|May 16, 2018
ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment DecisionMaciej J Zamek-Gliszczynski, Xiaoyan Chu, Jack A Cook, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 15, 2015
Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study designCaroline A Lee, Meeghan A O'Connor, Tasha K Ritchie, et al.
Journal of Pharmaceutical Sciences|September 27, 2014
The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performanceArzu Selen, Paul A Dickinson, Anette Müllertz, et al.
The AAPS Journal|June 12, 2012
Summary workshop report: Facilitating oral product development and reducing regulatory burden through novel approaches to assess bioavailability/bioequivalenceJames E Polli, Jack A Cook, Barbara M Davit, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The AAPS Journal|December 3, 2020
Correction to: Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug ProductsArzu Selen, Anette Müllertz, Filippos Kesisoglou, et al.
Rapid Communications in Mass Spectrometry : RCM|April 30, 2003
Investigation of EDTA anticoagulant in plasma to improve the throughput of liquid chromatography/tandem mass spectrometric assaysNalini P Sadagopan, Wenlin Li, Jack A Cook, et al.
Clinical Pharmacology and Therapeutics|April 5, 2022
Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance StudiesArnab Mukherjee, Shinichi Tsuchiwata, Timothy Nicholas, et al.
Molecular Pharmaceutics|December 23, 2009
Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studiesJack A Cook, Bo Feng, Katherine S Fenner, et al.
The AAPS Journal|June 3, 2010
Meeting report: applied biopharmaceutics and quality by design for dissolution/release specification setting: product quality for patient benefitArzu Selen, Maria T Cruañes, Anette Müllertz, et al.
Journal of Pharmaceutical Sciences|September 24, 2016
Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring GridPaul A Dickinson, Filippos Kesisoglou, Talia Flanagan, et al.
Clinical Pharmacology and Therapeutics|May 16, 2018
ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment DecisionMaciej J Zamek-Gliszczynski, Xiaoyan Chu, Jack A Cook, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 15, 2015
Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study designCaroline A Lee, Meeghan A O'Connor, Tasha K Ritchie, et al.
Journal of Pharmaceutical Sciences|September 27, 2014
The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performanceArzu Selen, Paul A Dickinson, Anette Müllertz, et al.
The AAPS Journal|June 12, 2012
Summary workshop report: Facilitating oral product development and reducing regulatory burden through novel approaches to assess bioavailability/bioequivalenceJames E Polli, Jack A Cook, Barbara M Davit, et al.
Pageof 3